What Bioferon (Interferon Alfa) Treats: Main Uses and Benefits

The therapeutic application of Interferon Alfa is focused on chronic, systemic diseases where control over viral activity or abnormal cell growth is required. The treatment is commonly used to help with conditions presenting with systemic or localized discomfort to provide supportive, long-term therapeutic benefits for the patient. The medication is applied across multiple high-stakes therapeutic areas.

---

Key Therapeutic Domains

Interferon Alfa is used for managing conditions characterized by periods of heightened symptoms related to persistent systemic viral presence, such as chronic Hepatitis B and Hepatitis C, that may be part of the risk of long-term disease progression. Furthermore, it is applied in clinical settings that involve unstable symptom patterns resulting from uncontrolled cell proliferation in specific hematologic malignancies (like Hairy Cell Leukemia) and solid tumors (such as Malignant Melanoma and Kaposi's Sarcoma). The therapy contributes to easing the overall symptom load by supporting the reduction of lesions in localized conditions like Condyloma Acuminata (Genital Warts).

“This approach is relevant when supportive symptom management is appropriate in complex diseases requiring systemic control over viral or cell proliferation activity.”

---

Quick Fact: Relief for Systemic Imbalance

Focus Area	Patient Benefit
Chronic Viral Activity	Assists with achieving SVR, reducing functional stress associated with long-term progression.
Malignant Cell Growth	Supports the management of conditions where functional stability is affected, easing symptomatic burden.
Persistent Lesions	Contributes to easing the symptom load by supporting the reduction of physical manifestations.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Bioferon (Interferon Alfa)?

Official regulatory documents define strict eligibility based on pre-existing health conditions, organ function, and age.

Category	Regulatory Statement
Populations for whom use is allowed	Adult patients (18 years and older) with compensated liver disease in approved indications.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Interferon Alfa. Patients with existence of, or history of, severe psychiatric disorders (e.g., severe depression, suicidal ideation). Patients with decompensated liver cirrhosis or autoimmune hepatitis. Patients with severe pre-existing cardiovascular disease or recent myocardial infarction or stroke.
Age-related eligibility rules	Adults: Standard labeled use. Pediatrics: Safety and efficacy are generally not established for those under 18 years old for most malignancy indications, although specific labels permit use in children as young as 1 year for chronic viral hepatitis.
Pregnancy and lactation eligibility status	Pregnancy: Monotherapy is generally not recommended; combination therapy with ribavirin is contraindicated. Lactation: Not recommended during treatment and for a specified period after the final dose.
Eligibility-related restrictions	Use is restricted for patients with severe renal impairment or pre-existing thyroid disease that is not adequately controlled. Females of reproductive potential and their male partners must use effective contraception during and after therapy.

These explicit regulatory statements (e.g., "contraindicated," "not established") determine the official boundaries for use, ensuring the medicine is reserved for adult populations meeting specific health criteria documented in the prescribing information.

Bioferon (Interferon Alfa) Interactions with Other Medicines and Products

Official regulatory information identifies specific drug combinations and substance categories that may interact with Interferon Alfa, primarily through effects on drug metabolism and additive adverse effects.

Documented High-Risk Combinations

Classification	Interacting Substance/Condition
Conditional Contraindication	Ribavirin (in combination therapy for pregnant women and male partners of pregnant women)
Formal Contraindication	Fezolinetant
Avoid Use	CNS Depressants (e.g., Narcotics, Sedatives)
Avoid Use	Myelosuppressive Agents (e.g., Zidovudine)

Pharmacokinetic and Exposure Cautions

Interferon Alfa can affect the metabolism of other drugs by inhibiting the CYP450 enzyme system, notably CYP1A2. This can lead to decreased clearance and increased plasma levels of co-administered medicines, such as Theophylline (a xanthine derivative) and Fezolinetant. Closely monitoring patients who are taking drugs with a narrow therapeutic index (like Theophylline or Warfarin) is required due to the potential for altered exposure.

Population-Specific Interaction Notes

Patients with renal impairment should be managed with caution. Regulatory guidance notes that the drug's effects may be increased due to slower removal (reduced clearance) from the body in this population.

Bioferon, an Interferon Alfa molecule, functions as an agonist by binding to the heterodimeric Type I interferon receptor (IFNAR) complex on the surface of target cells. This receptor complex comprises the subunits IFNAR1 and IFNAR2. Upon binding, Interferon Alfa induces a conformational change in the receptor, leading to the rapid activation and cross-phosphorylation of receptor-associated Janus Kinases, specifically JAK1 and TYK2.

This phosphorylation event creates docking sites for the STAT1 and STAT2 proteins. JAK1 and TYK2 phosphorylate the recruited STAT proteins, causing them to dissociate from the receptor. Phosphorylated STAT1 and STAT2 heterodimerize and then associate with IRF9 to form the Interferon-Stimulated Gene Factor 3 (ISGF3) transcription complex. This active complex translocates into the cell nucleus and binds to Interferon-Stimulated Response Elements (ISREs) in the promoter regions of various Interferon-Stimulated Genes (ISGs). The resulting downstream cascade involves the transcriptional upregulation of hundreds of ISGs, whose encoded proteins modulate key cellular processes, leading to broad system-level physiological modulation of the innate and adaptive response systems.

Administration Overview

Bioferon (Interferon Alfa) is typically administered via injection. The method of administration is usually subcutaneous (under the skin) or intramuscular (into a muscle). The specific technique used often depends on the underlying condition being treated and the guidance provided by a healthcare professional.

Preparation and Storage

Proper handling of the medication is necessary to maintain its stability. The product is generally stored in a controlled, refrigerated environment. Before administration, the medication is checked for clarity and the absence of particulate matter. If the solution appears discolored or contains visible particles, it is typically not used.

Self-Administration Process

For patients who manage their treatment at home, a healthcare provider typically demonstrates the correct procedure for preparation and injection. This includes:

• Site Selection: Rotating injection sites is a common practice to reduce the risk of skin irritation or tissue damage. Common areas for subcutaneous injection include the thighs, abdomen, or upper arms.
• Aseptic Technique: Ensuring the injection site and hands are cleaned thoroughly before beginning the process to minimize the risk of infection.
• Disposal: Used needles and syringes are placed in puncture-resistant containers immediately after use to ensure safe disposal.

Monitoring Treatment

Regular follow-up appointments are a standard part of using this medication. These sessions allow for the monitoring of the body's response to the therapy through various diagnostic tests, such as blood counts and liver function assessments. Maintaining a consistent schedule for administration is often emphasized to support the stability of the medication levels in the system.

Research Evidence / Overview of Studies for Bioferon (Interferon Alfa)

This section summarizes the official research evidence for Interferon Alfa, describing what the studies examined, what they observed, and what remains uncertain, based on authoritative scientific and regulatory sources. This information is for context and does not offer clinical advice.

---

Evidence from Studies for High-Risk Malignant Melanoma

What the Research Examined

Interferon Alfa was studied for use as an adjuvant treatment, meaning it was evaluated in patients who had undergone surgery to remove high-risk melanoma (typically Stage IIB or Stage III) to see if it was associated with changes in recurrence risk. The key outcomes researched were the time until the cancer recurred (Relapse-Free Survival or RFS) and the length of patient survival (Overall Survival or OS).

What the Studies Reported

Findings from multiple systematic reviews and combined trial analyses reported patterns related to extended Relapse-Free Survival, meaning the time until recurrence was observed in relation to the treatment group. However, when studies explored the crucial outcome of Overall Survival, the findings were mixed and varied across studies.

What Remains Uncertain

The lack of consistent evidence across all major trials means that the certainty regarding findings for overall survival remains low for the general population studied. Additionally, data are still emerging on how to accurately identify the specific patient groups who may experience a difference in long-term survival. Research is ongoing to clarify the optimal treatment duration and dosage.

---

Evidence from Studies for Chronic Viral Hepatitis

What the Research Examined

Interferon Alfa was evaluated in clinical trials for patients with chronic infections of Hepatitis B (CHB) and Hepatitis C (CHC). The goal of these trials was studied for achieving virologic remission, meaning the sustained absence of detectable virus in the bloodstream (Sustained Virologic Response or SVR), and monitoring liver enzyme normalization.

What the Studies Reported

For Chronic Hepatitis B, trials reported how symptoms evolved and data showed patterns related to the loss of certain viral markers (e.g., HBeAg seroconversion) in some observed patient groups. For Chronic Hepatitis C, combination therapy trials involving Interferon Alfa reported different SVR measurements, which were observed in relation to monotherapy.

What Remains Uncertain

While the historical evidence established that Interferon Alfa was studied for these conditions, the context of care has evolved since these studies were conducted. For Hepatitis C, all-oral treatments are now available. Therefore, the historical research contributes to the broader evidence landscape, but the context of care has evolved since these studies were conducted. Comparative evidence is lacking against the newest therapies.

---

What the Evidence Landscape Still Shows as Uncertain

Certainty remains low for some outcomes due to inconsistent findings in major trials, particularly regarding Overall Survival in high-risk melanoma. Additionally, the overall shift in standards of care for chronic Hepatitis C renders much of the older Interferon Alfa research primarily historical, and the comparative evidence is lacking against modern oral agents. In many indications, follow-up durations were limited for assessing the absolute, decades-long outcome.

Key Studies & References

1. Interferon and Hepatitis B: Current and Future Perspectives

Common questions about Bioferon (Interferon Alfa) (FAQ)

---

Q: What does the acronym MIU stand for?

According to the official product information, the dose of Interferon Alfa is specified in International Units (IU) or Million International Units (MIU). The 'M' in MIU stands for Million, meaning one MIU is equivalent to one million International Units. This unit is used to standardize the drug's biological activity.

Q: Which specific patient groups may benefit from this treatment?

Regulatory documents state that this medicine is approved for specific adult populations. These approved uses may include certain stages of melanoma, as well as managing chronic viral infections such as chronic hepatitis B and chronic hepatitis C, depending on the specific label. Treatment is reserved for patients who meet defined eligibility criteria.

Q: Can I stop taking Bioferon if the side effects are too bad?

Official prescribing information includes detailed protocols for managing intolerance and side effects. These regulatory guidelines detail specific instructions for dose reduction or temporary cessation of treatment if certain laboratory changes or severe toxicities occur. Regulatory guidelines describe the predefined criteria your healthcare provider may use to assess the need for changes to therapy, including temporary cessation or permanent discontinuation.

Q: Why is it important to rotate the injection site when using this medicine?

Official administration instructions emphasize the requirement to rotate the injection site during subcutaneous (SC) administration. The product label suggests rotating the site; this practice is generally done to help minimize local adverse reactions at the injection site, such as irritation or changes to the skin. Rotating the site can also help ensure the medicine is absorbed consistently.

Q: How long does a typical course of Bioferon treatment last?

The required duration of therapy varies significantly depending on the specific approved condition being treated. For instance, some protocols for melanoma may involve an initial phase followed by maintenance for up to several years. Treatment for conditions like chronic hepatitis is generally defined for a specific period, such as 48 weeks, as outlined in the official dosing regimen.

Q: Does this drug interfere with birth control or increase the risk of pregnancy?

Official regulatory warnings emphasize the need for both male and female patients to use effective contraception throughout the treatment period. While the drug is not generally recommended as monotherapy during pregnancy, combination therapy with other agents is formally contraindicated. In some cases, the medication may be noted to affect the menstrual cycle or reproductive system, though the primary warning relates to combination use.

Q: What do I do if I miss a scheduled dose of Bioferon?

Official product labeling provides guidance for handling missed doses. The product labeling typically indicates that if a dose is missed by only one or two days, it should be taken as soon as possible, then continuing the regular schedule. If a longer period has passed, the prescribing information directs users to contact their healthcare provider for specific guidance.

Q: How should the used needles be disposed of?

The official instructions mandate that all used needles and syringes be placed immediately into an FDA-cleared sharps disposal container. The regulatory guidance indicates that users must follow the specific procedures established by their local community, state, or federal guidelines for the safe final disposal of the full sharps container.

Storage and Disposal Requirements for Interferon Alfa

Official regulatory documents define strict storage and disposal requirements for this biologic medicine to maintain its stability and ensure safety.

Required Storage Conditions

Condition	Requirement
Temperature	Store in a refrigerator between 2 °C and 8 °C (36 °F and 46 °F). Do not freeze.
Protection	Keep the product in its original carton to protect it from light. Keep away from heat.
Child Safety	Store all medicine and supplies out of the reach of children.

Stability and Handling Rules

Unused multi-dose vials must be discarded one month after the initial dose, even if refrigerated. Solutions reconstituted from powder must be discarded after 24 hours if not used immediately. The solution should be visually checked and must not be used if it appears cloudy or contains particles.

Proper Disposal Instructions

Used needles and syringes must be placed immediately into an FDA-cleared sharps disposal container. Do not throw loose needles or syringes in the household trash. Final disposal of the sharps container must follow local community guidelines.